STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma

Autor(es)

Ihlaseh-Catalano, Shadia M. ^[1] ; Drigo, Sandra A. ^{[2, 3]} ; de Jesus, Carlos M. N. ^[4] ; Domingues, Maria Aparecida C. ^[1] ; Trindade Filho, Jose Carlos S. ^[4] ; de Camargo, Joao Lauro V. ^[1] ; Rogatto, Silvia R. ^{[2, 3]}

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Sch Med, Dept Pathol, UNESP, Botucatu, SP - Brazil

^[2] Sao Paulo State Univ, Sch Med, Dept Urol, NeoGene Lab, UNESP, Botucatu, SP - Brazil

^[3] AC Camargo Canc Ctr, CIPE, Sao Paulo - Brazil

^[4] Sao Paulo State Univ, Sch Med, Dept Urol, UNESP, Botucatu, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Histopathology; v. 63, n. 5, p. 678-685, NOV 2013.
• Citações Web of Science: 13

Resumo

AimsTo investigate the prognostic value of expression levels of the genes STEAP1 and STEAP2, and of STEAP1 protein, in prostate carcinomas (PCa). Methods and resultsSTEAP1 and STEAP2 transcript levels were evaluated by RT-qPCR in samples from 35 PCa, 24 adjacent non-neoplastic prostate (AdjP) tissues, five cases of benign prostatic hyperplasia (BPH), and two histologically normal prostates (N). STEAP1 expression was assessed by immunohistochemistry in samples from 198 PCa, 76 AdjP, 22 BPH, and two N. The findings were compared with clinical and pathological parameters and patient outcome. STEAP1 and STEAP2 transcript analysis showed no differences between the groups tested. Although not significant, higher STEAP1 mRNA levels were detected in tumours with high Gleason scores and in patients who presented with biochemical recurrence (BCR). STEAP1 overexpression was detected in PCa, and was significantly associated with high-grade Gleason scores, seminal vesicle invasion, BCR, and worse outcome (metastasis or PCa-specific death). STEAP1 overexpression was significantly associated with shorter BCR-free survival. Multivariate analysis revealed that STEAP1 is an independent marker for BCR. ConclusionsThese findings provide evidence that STEAP1 is a biomarker of worse prognosis in PCa patients. (AU)

• Processo FAPESP: 04/10028-0 - Assinatura genetica em carcinomas de prostata e suas metastases.
• Beneficiário: Silvia Regina Rogatto
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 08/57887-9 - Instituto Nacional de Oncogenômica
• Beneficiário: Luiz Paulo Kowalski
• Modalidade de apoio: Auxílio à Pesquisa - Temático